Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Ph-like ALL Should Be Treated as the Other B ALL After Demonstration of the Right Target and Best Trial / Registry Context

10 views
December 13, 2019
0 Comments
Login to view comments. Click here to Login
Hematologic Oncology